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1. Introduction  
Over one hundred years of innovative experimentation with the “common fruit fly” or 
Drosophila melanogaster has placed this remarkable organism at the forefront of 
contemporary biological research. Whether we consider the implications of modern genetic 
technologies and comprehensive genomic research, or we are interested in leading-edge 
aspects of molecular and cellular biology or complex developmental biology systems, or our 
studies range from the pin-point accuracy of proteomics to the large-scale questions of 
population biology, research with fruit flies has made very significant contributions to our 
understanding of the basic and complex functions of life. Although research into a wide 
range of biological questions has benefited greatly from experimentation with Drosophila, it 
never fails to surprise how often an approach that uses this model organism is undervalued 
or ignored. Any experimental system can be and should be criticized; however the 
opportunity to explore the biological basis of disease should never be missed. One shining 
example of this point is our understanding of Parkinson disease which has expanded 
through and continues to benefit from basic research into the biology of Drosophila, a model 
organism whose genome has been so thoroughly understood as to make it indispensable for 
medical research. These recent advances provide significant support for the use of Drosophila 
melanogaster models in the study of the biological basis of many human diseases and 
disorders. 
Parkinson disease is the most common movement disorder and the second most common 
neurodegenerative disorder. Most apparent to even the most casual of observers is the fact 
that patients with Parkinson disease present with symptoms that are related to locomotion 
and motor control. These symptoms include resting tremor, slowness of movement, rigidity 
and postural instability. As the common underlying source that gives rise to these 
movement difficulties, Parkinson disease is most often associated with and distinguished by 
the degeneration of neurons, especially the dopamine-producing, or dopaminergic, neurons 
in the substantia nigra of the midbrain and the subsequent loss of dopamine (Dauer & 
Przedborski, 2003). Associated with these degenerating neurons is the appearance in many 
cases of the disease of large aggregates of proteins that are often referred to as the Lewy 
bodies.  Often ignored are the additional non-motor symptoms, where non-dopaminergic 
neurons including olfactory and brain stem neurons, can frequently deteriorate before the 
dopaminergic neurons show signs of loss (Braak et al., 2003). Additional Parkinson disease 
symptoms are common and comprise a number of behavioural symptoms that include 
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dementia, depression, anxiety and difficulties with sleep, plus non-behavioural symptoms 
such as the development of muscular and skeletal anomalies and skin lesions (Simuni & 
Sethi, 2008). Given the importance and the complexity of this disease, the application of a 
multifaceted, interdisciplinary approach to understanding the biological basis of Parkinson 
disease, including the modelling of the disease in well-known genetically versatile 
organisms, cannot be stressed enough. 
The inherited or familial forms of Parkinson disease are, for the most part, indistinguishable 
in nature and severity from the sporadic forms of the disease (Hardy et al., 2009). As of only 
a few years ago, Parkinson disease was believed to be completely sporadic in nature, yet the 
identification of the inherited forms of the disease along with subsequent characterization of 
the causative genetic defects has revolutionized this area of research. It is now known that 
the familial cases comprise approximately 10 to 15% of the cases and arise from mutations in 
several identified genes with new loci associated with Parkinson disease being routinely 
discovered. Of the loci identified early in this process, mutations in the alpha-synuclein gene 
(designated as both PARK1/PARK4) (Polymeropoulos et al., 1997; Singleton et al., 2003) and 
Leucine-rich repeat kinase 2 or LRRK2 (identified as PARK8) (Paisan-Ruiz et al., 2004; Zimprich 
et al., 2004) cause autosomal dominant or “gain-of-function” forms of the disease.  
Mutations in the parkin gene (designated as PARK2)(Kitada et al., 1998), PTEN-induced kinase 
1 or Pink1 (PARK6)(Valente et al., 2004), and Dj-1 (PARK7) (Bonifati et al., 2003) are 
associated with autosomal recessive or “loss-of-function” forms of Parkinson disease. With 
the identification of the underlying genetic contributions to, at the very least, a sizable 
proportion of the incidents of Parkinson disease, it has become possible to apply the 
principles of disease modelling in genetically tractable animal systems to the study of this 
disease. 
To demonstrate the great utility of the application of research into Drosophila melanogaster 
in the modelling of Parkinson disease, I will describe some of the most exciting recent 
advances in this field. To begin, a brief description of the wealth of genetic and transgenic 
approaches that are most commonly used to model aspects of human disease in 
Drosophila will be provided as an introduction to the organism. The first model of 
Parkinson disease, one based upon the toxic expression of the human alpha-synuclein gene, 
the first gene identified as a genetic cause of Parkinson disease, will be discussed. This 
model offered the opportunities to study a wide range of biological contributions to 
Parkinson disease including aspects of protein structural stability, oxidative stresses and 
other disease genes.  Investigation of Lrrk/LRRK2 in flies has revealed roles in dopamine 
distribution, protein synthesis and cell death in another model of a dominant form of 
Parkinson disease. Then, the processes of modelling Parkinson disease through 
examination of the loss-of–function of the Drosophila homologues of the parkin and Pink1 
genes, both responsible for recessive forms of Parkinson disease will be detailed. Of a 
very significant nature, this area of research has lead to the fundamental understanding 
the activity of these gene products at the mitochondria. Furthermore, recent studies have 
lead to the proposal of a mechanism that outlines the normal role of parkin and Pink1 in 
mitochondrial dynamics. It is very likely that the loss of this mechanism leads to failure of 
the cell’s ability to clear damaged mitochondria and ultimately results in the degeneration 
of these cells and, subsequently, the disease state. Finally, continued study of Drosophila 
models of Parkinson disease is clearly well positioned to contribute a great deal to the 
future of research into the basis of this disease. 
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2. The Drosophila approach to model human disease 
Drosophila melanogaster has been extensively studied and a wealth of genetic, genomic, 
cellular and developmental knowledge and reagents are readily available. Drosophila are 
inexpensive to propagate and can produce a large number of genetically homogenous 
progeny. Flies display surprisingly intricate behaviours and have complicated brain and 
nervous systems. For many purposes, the fly provides a well-characterized system that is 
relatively easy to manipulate but complex enough to be relevant to the development of 
human disease models. 
Often, once a gene has been implicated in a given disease, a bioinformatic search of genomic 
sequences can readily identify a potential homologue or orthologue from among the genes 
that comprise the well-characterized genome of Drosophila melanogaster as well as the 
genomes of a number of other Drosophila species for comparison. Application of reverse 
genetics can lead the production of both loss-of-function and gain-of-function phenotypes 
that may recapitulate symptoms of a given disease. Loss-of-function can be achieved either 
through the creation of mutations that lower or abolish gene activity or through the directed 
expression of an interfering RNAi transgene. A gain of function phenotype can be generated 
by the directed expression of a gene to where there is normally low or no expression or by 
inducing elevated levels of expression far above the norm. As a very well studied system, 
the Drosophila’s pre-existing loss-of-function mutations, as well as transposon-bearing lines 
that can be employed to direct the expression, are available through stock centres and 
individual research laboratories from around the world. Due to the genomics projects, it is 
easy to access cDNA and genomic clones along with various vectors for generation of a 
variety of transgenic animals.  
2.1 Drosophila genetics: genes, mutants and transgenics 
In most cases, genes that have been identified as playing a role in human disease have 
counterparts in the genome of Drosophila melanogaster. Through the analysis of pre-existing 
mutants, the application of genetic screens to generate novel loss-of-function mutants and 
the implementation of “interfering RNA” or RNAi technology to reduce or eliminate gene 
activity can mimic the effect of recessively inherited diseases. For dominantly inherited 
disease, some pre-existing dominantly inherited alleles may exist in the stock centre 
collections.  However, hypermorphic gain-of-function phenotypes can be generated by the 
directed overexpression of a transgene introduced into the fly genome through germ-line 
transformation. In addition, neomorphic and antimorphic gain-of-function phenotypes may 
be produced by in vitro construction and transformation of Drosophila transgenes that 
replicate molecular defects that have been determined to cause disease in people. 
Alternatively, a transgene that can express a variant form of a human gene can be fashioned 
and transformed. This approach has been applied to study the function and the potential 
contribution of genes to a number of diseases, including Parkinson disease.  This approach 
can be instrumental in providing insight into the function of an identified gene involved in a 
human disease when the function is difficult to determine. 
To produce the gain-of-function or the RNAi loss-of-function phenotypes described above, 
the Gal4/UAS system has been widely employed for the ectopic expression of specific genes 
in Drosophila (Brand & Perrimon 1993). For the most part, a gene of interest is cloned within 
a P element transposon-bearing plasmid containing several copies of the DNA-binding 
target of the yeast transcription factor GAL4 designated as the ‘Upstream Activating 
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Sequence’ (UAS) along with a selectable marker to readily track the presence of the 
transgene. As there is no Drosophila transcription factor that acts though binding of this 
sequence, in the absence of GAL4 these fusion transgenes are mostly inactive. Once 
established, individuals bearing a responsive transgene can be mated to specific lines that 
express Gal4 in any one or combination of expression patterns. Many choices of 
expression are available including ubiquitous, pan-neural, dopaminergic neuron-specific, 
early or late in eye development, inducible by heat shock, and many more. When the Gal4 
transgene and the UAS target gene are combined in the offspring of the controlled 
breeding experiments, the gene of interest is subject to control of expression with regard 
to level, timing and tissue specificity. Analyses of these progeny provide the opportunity 
to approach a wide range of fundamental biological investigations including the detailed 
modelling of human disease.  
When dealing with living systems, and in particular when carrying out complex 
manipulation of a model organism, careful evaluation and consideration of the techniques 
employed are necessary. With this in mind, it is important to note that a very limited 
number of Gal4 transgenes had been demonstrated to lead to cell death: first in the neuron-
rich compound eye (Kramer & Staveley, 2003) and later in the nervous system (Rezaval et 
al., 2007). This suggests that the use of the Gal4/UAS system requires some caution because 
there may be a compounding Gal4-effect in some experiments when interpreting 
experimental observations. As always, control experiments must be subjected to proper 
evaluation and scrutiny. Nevertheless, the Gal4/UAS ectopic gene expression system in 
Drosophila is an extremely powerful tool and is one of the reasons that modelling human 
disease in flies is such an attractive pursuit. 
2.2 Drosophila dopaminergic neurons 
For a model system to functionally approach a condition as complex as Parkinson disease, 
changes to specific tissues that result in recapitulation of phenotypes that resemble 
symptoms of the disease are key. The Drosophila adult brain has been characterized to 
contain clusters of dopaminergic neurons (Nassel & Elekes, 1992). The feeding of rotenone, 
the complex I inhibitor that initiates degeneration of dopaminergic neurons in mammals, 
can cause the loss of these clusters of dopaminergic neurons in flies (Coulom & Birman, 
2004). This demonstrates that there is a susceptibility of dopamine-producing neurons to 
toxins that is conserved between mammals and flies. As described below, altering the 
expression of selected genes in these dopaminergic neurons has resulted in loss of the 
neurons coupled with an age-dependent loss of locomotor abilities. The basic similarities 
between the genetically manipulated Drosophila models and Parkinson disease patients, 
given that the loss of the dopamine-producing neurons and the subsequent change in 
behaviour occurs over time, suggests that significant aspects of the disease may be well 
modelled in flies.  
3. The alpha-synuclein-dependent Drosophila model of Parkinson disease 
Once the genetic basis of a familial form of Parkinson disease was identified (the alpha-
synuclein gene or PARK1 and, later, PARK4 as well) and the molecular basis of the defect 
determined (as specific changes to the protein), exploring the function or dysfunction of this 
gene was greatly aided by study in the Drosophila system.  
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3.1 The alpha-synuclein gene (PARK1) models Parkinson disease in Drosophila 
Although instances are rare, mutations that result in substitution of amino acid residues 
within the human alpha-synuclein protein, specifically A30P, A53T and E46K, produce a 
dominant autosomally inherited version of Parkinson disease (PARK1; Polymeropoulos et 
al. 1997; Kruger et al. 1998; Zarranz et al. 2004). An early onset familial version of Parkinson 
disease results when a duplication of the region bearing this gene produces an increase in 
gene copy number (PARK4; Singleton et al. 2003). Although abundant in Lewy bodies, the 
precise physiological function of alpha-synuclein is uncertain. Because two of the original 
designated PARK loci (PARK1 and PARK4) have mapped to the alpha-synuclein gene, the 
native role and consequences of dysfunction appear complex and deserve to undergo 
extensive evaluation. 
It is of extreme importance to the modelling of Parkinson disease in Drosophila that the first 
and most exploited Drosophila model of Parkinson disease depends upon the Gal4/UAS 
system for the ectopic expression of various forms of the human alpha-synuclein gene 
(Feany & Bender, 2000). Expression of human wild-type and Parkinson disease-causing 
mutant forms of alpha-synuclein in Drosophila results in the loss of the dopamine-producing 
neurons. The loss of neurons is coupled with the loss of the ability to climb over time in 
adult flies. As well, the development of Lewy body-like cytoplasmic inclusions and 
degeneration of the retina occurs with the expression of A30P, A53T and wild-type versions 
of alpha-synuclein using different Gal4 drivers. The observed phenotypic end-points 
produced by the disease-associated forms of the alpha-synuclein protein appear to display 
some differences and may mirror aspects of the toxicity that lead to various sub-types of 
Parkinson disease. To be clear, bioinformatic analysis of the genome of Drosophila 
melanogaster has not identified genes that encode any member of the synuclein family of 
proteins, including alpha synuclein. However, the recapitulation of phenotypes in 
Drosophila caused by the toxicity of alpha-synuclein gene product that somewhat mimic the 
consequences of Parkinson disease certainly seems to validate such study in this model 
organism. As with Parkinson disease patients, Drosophila models of Parkinson disease 
involve multiple defects, the cellular basis that provides insight into the pathogenesis of 
Parkinson disease. 
3.2 Controversial detection of neurodegeneration in the model  
Briefly, visualization of the dopaminergic neurons in Drosophila brains or brain sections has 
been accomplished through two main methods: detection of the tyrosine hydroxylase 
enzyme via immunohistochemistry, or detection of a green fluorescent protein or GFP reporter 
gene placed under the control of the tyrosine hydroxylase-Gal4 transcription factor. For the 
most part, the determination of the specific death of dopaminergic neurons over time in 
response to the expression of alpha-synuclein has been demonstrated reproducibly since 
development of the alpha-synuclein-induced Drosophila model of Parkinson disease (Feany 
& Bender, 2000; Auluck et al., 2002; Cooper et al., 2006; Wassef et al., 2007; Botella et al., 
2008; Trinh et al., 2008). Not all studies could detect dopaminergic neurodegeneration using 
anti-tyrosine hydroxylase immunostaining (Pesah et al., 2005) or detection of transgenic GFP 
(Whitworth et al. 2006). Clearly differences in the approach or methodology used to 
measure loss of dopaminergic neurons can influence the sensitivity of the assay (Auluck et 
al., 2005). In addition, as a definite decrease in the strength of the nuclear GFP signal has 
been observed the dopaminergic neurons of ageing flies that express alpha-synuclein, (Botella 
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et al. 2008) a significant proportion of the differences could have easily been overlooked. In 
primary cultures of neurons cultivated from Drosophila that express alpha-synuclein, an in 
vitro model for Parkinson disease that shows great potential, the observed decrease in 
detection of GFP in these cultured neurons has been strongly associated with the early 
stages of apoptosis and signs of neurodegeneration (Park et al., 2007). Although this has 
been a contentious issue, the loss of immunological staining of the tyrosine hydroxylase 
enzyme, or detection of the tyrosine hydroxylase-responsive GFP reporter, seems to be very 
well correlated to neuronal dysfunction and degeneration. 
This controversy highlights one great advantage of the study of Parkinson disease in an 
organism that presents complex phenotypes that reflect the consequences of the disease in 
humans. Of great importance, experiments where the loss of neurons is correlated to the loss 
of locomotor ability over time have provided sufficient comparison. For example, when 
oxidative stress is prevented, the loss of locomotor activity and the loss of dopaminergic 
neurons are diminished together in flies expressing alpha-synuclein (Pendleton et al., 2002, 
Yang et al., 2003, Wassef et al., 2007, Botella et al., 2008). As such, the loss of climbing ability 
seems to be a meaningful and modifiable phenotype that allows for the detection and 
validation of subtle influences. 
3.3 Mechanisms to prevent alpha-synuclein-dependent toxicity  
To address the possibility that chaperone activity may actively counteract protein toxicity, 
elevated expression of Heat Shock Protein 70 (HSP70) was demonstrated to toxicity of a-
synuclein expression although aggregates were found (Auluck et al., 2002). Reduced 
chaperone activity contributed to increased loss of neurons resulting from expression of 
alpha-synuclein.  Providing transgenic flies with geldanamycin, an inducer of chaperone 
activity, added to the food source contributed to survival of alpha-synuclein-expressing 
neurons (Auluck et al., 2005). The phosphorylation of alpha-synuclein at residue Serine 
residue-129, a modification often found in brains from Parkinson disease patients, 
apparently leads to toxicity (Fujiwara et al., 2002). In Drosophila melanogaster, study of the 
consequences of in vivo alteration of this site of phosphorylation suggests that this amino-
acid residue is responsible for keeping the alpha-synuclein protein in a soluble form instead 
of in a state of  aggregation (Chen & Feany, 2005). Prevention of phosphorylation at this site 
results in aggregation and reduced toxicity. This observation supports the hypothesis that 
the soluble form of the protein has a much greater potential for toxicity than does the non-
phosphorylated form. Taken all together, this suggests that the process of aggregation acts 
as a protective cellular mechanism that works to neutralize the toxic forms of the alpha-
synuclein protein. 
While oxidative stress seems to contribute to Parkinson disease, a relationship to the 
mechanism behind alpha-synuclein toxicity is unclear. The degeneration of neuronal 
phenotypes induced by expression of mutant forms of alpha-synuclein is enhanced growth 
under conditions of hyperoxia while the elevated expression of the oxygen free radial 
scavenger superoxide dismutase suppresses the neuronal degeneration and the loss of 
locomotor activity over the lifespan of alpha-synuclein-expressing flies (Botella et al., 2008). 
To support the role of oxidative insult in the disease process, the alpha-synuclein-induced 
phenotypes are suppressed by other known antioxidants. These include the overexpression 
of methionine sulfoxide reductase and the supplementation of the Drosophila growth 
medium with S-methyl-L-cysteine (Wassef et al., 2007), and the induction of glutathione 
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synthesis or glutathione conjugation activity (Trinh et al., 2008). As the toxicity of alpha-
synuclein is sensitive to oxidative stress, manipulation of antioxidants may make a 
significant contribution to modify these effects. 
One of the great advantages of employing the Drosophila model is the ability to combine 
and evaluate various components identified to contribute to Parkinson disease in an animal 
model organism. The first example of combining gene products that are known to cause 
inherited forms of Parkinson disease was the demonstration that the overexpression of 
parkin can act to counteract the toxic effects of both wild type and mutant forms of alpha-
synuclein to restore climbing ability and to prevent degeneration of the retina when co-
expressed in the eye (Haywood & Staveley, 2004; 2006). Similarly, the directed expression of 
Pink1, an upstream activator of parkin, acts to restore locomotor abilities and prevent subtle 
developmental defects in the eye (Todd & Staveley, 2008). This approach demonstrates that 
the directed expression of some of the recessive Parkinson genes can act to balance defects 
caused by a dominantly inherited Parkinson disease gene. 
4. The LRRK2/Lrrk (PARK8) models of Parkinson disease in Drosophila 
Leucine-rich repeat kinase 2 or LRRK2 (first identified as PARK8) causes an autosomal dominant 
or “gain-of-function” form of Parkinson disease (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). 
Dysfunction of LRRK2 has been mapped to several amino-acid substitutions in the protein and 
is very prominent among sporadic and inherited forms of Parkinson disease. The LRRK2 gene 
encodes a very large protein with a leucine-rich repeat (LRR) domain, a kinase domain, a RAS-
like GTPase domain and WD-40 domain and is very similar to an orthologous gene LRRK1.  
There is a single homologue, Lrrk, in Drosophila melanogaster. Perhaps due to difficulties in 
the detection of neurodegeneration, as discussed above, there has been some confusion with 
studies of Lrrk/LRRK2 in flies. In one case, Lrrk mutant flies display impaired locomotive 
activity and a reduction in the immunostaining of tyrosine hydroxylase in dopaminergic 
neurons (Lee et al., 2007). While the dopaminergic neurons display abnormal morphologies, 
the absolute number of the neurons appears to be unchanged although they may be 
degenerating slowly. Under other circumstances, Lrrk mutants seemed relatively normal 
which lead to the claim that Lrrk is not required for the survival of dopaminergic neurons 
(Wang et al., 2008). Directed expression of wild type of Lrrk did not lead to detectable 
degeneration of dopaminergic neurons (Lee et al., 2007). However, expression of mutant 
forms of both human (G2019S) and Drosophila (I2020T) did lead to documented loss of 
dopaminergic neurons (Imai et al., 2008; Liu et al., 2008). Nevertheless, the few studies of 
Lrrk/LRRK2 in flies have revealed a great deal that may influence our understanding of 
Parkinson disease. 
The Lrrk mutants undergo lipid peroxidation and mutant flies containing the carboxy-
terminal kinase domain truncated Lrrk transgene are sensitive to hydrogen peroxide (Wang 
et al., 2008). However, Lrrk mutants seem to be reasonably resistant to the oxidative stresses 
presented by paraquat and hydrogen peroxide (Imai et al., 2008). The relationship between 
Lrrk/LRRK2 and oxidative stress is unclear for now. 
Lrrk/LRRK2 has been demonstrated to be involved in the negative regulation of normal 
levels of dopamine. The over expression of select mutants of Lrrk, but not wild-type Lrrk, 
causes a severe reduction in the dopamine levels of the brain (Imai et al., 2008). Treatment 
with I –DOPA causes improvement in movement not survival of dopaminergic neurons (Liu 
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et al., 2008). Conversely, dopamine content is highly elevated in Lrrk mutants, as changes in 
dopamine levels must not be due to survival neurons but due to either defects in 
metabolism or processing and handling. 
The eukaryotic initiation factor 4E (eIF4E)-binding protein, a major controller of protein 
synthesis and as such a key regulator of responses to cellular stress is phosphorylated by the 
Lrrk/LRRK2 kinase (Imai et al., 2008). This strongly suggests that the survival of 
dopaminergic neurons is compromised by pathogenic forms of Lrrk/LRRK2 through the 
deregulation or mis-regulation of protein translation. The Lrrk and LRRK2 proteins have been 
shown to phosphorylate and activate the transcription factor foxo (Kanao et al., 2010). This 
suggests that downstream targets of foxo, such as hid in flies (and Bim in humans), act to 
activate the apoptotic machinery to cause the neurodegeneration in Lrrk/LRRK2 models of 
PD. These research findings demonstrate a very meaningful connection between the control of 
protein synthesis, activation of cell death programs and the development of Parkinson disease. 
5. The parkin/Pink1-dependent Drosophila models of Parkinson disease 
5.1 The consequences of parkin and Pink1 loss in Drosophila 
The loss-of-function in the parkin gene (PARK2), which encodes a highly conserved ubiquitin 
E3 ligase, is responsible for a rare autosomal recessive subtype of Parkinson disease. The 
Drosophila parkin gene is highly expressed in the Drosophila central nervous system 
(Horowitz et al. 2001; Bae et al. 2003). In parkin mutants, the dopaminergic neurons degenerate 
(Greene et al., 2003; Cha et al., 2005; Whitworth et al., 2005; Wang et al., 2007). In flies that that 
overexpress some mutant forms of parkin, dopaminergic neurons degeneration occurs (Sang et 
al., 2007). Although viable, parkin mutants present with a reduction in life-span, locomotor 
defects and extensive degeneration of muscle fibres, the latter is clearly associated with 
mitochondrial deterioration (Greene et al., 2005). The male parkin mutants are sterile due to 
failure of mitochondrial activities during spermatogenesis (Riparbelli and Callaini, 2007). 
Reduction of neuronal-specific staining (either GFP or TH) and/or cell death has been reported 
in these parkin mutants (Greene et al., 2003; Cha et al., 2005; Whitworth et al., 2005; Wang et al. 
2007). The localization of this protein to the mitochondria (Darios et al., 2003) coupled with the 
consequences of parkin loss is a strong indication that it protects this organelle. 
Mutations in the PTEN-induced kinase 1 (Pink1 or PARK6) gene are a common cause of 
autosomal recessive Parkinson disease (Valente et al., 2004).  In flies, the Pink1 gene, like 
parkin, is highly expressed in adult heads and testes (Park et al. 2006). The Pink1 serine–
threonine kinase, along with a kinase domain, contains a mitochondrial-targeting signal 
(Clark et al., 2006). A decrease in the levels of dopamine with age plus a somewhat limited 
loss of dopaminergic neurons was found in the Pink1 mutants along with the presence of 
abnormal mitochondria in the surviving dopaminergic neurons. When the function of Pink1 
was inhibited through the directed expression of an RNAi transgene, loss of dopaminergic 
neurons as well as the age-dependent degeneration of ommatidia was observed (Wang et al. 
2006; Yang et al. 2006). The potential for a functional association with the mitochondria and 
the similarity in the consequences of dysfunction clearly suggest a shared role for these two 
proteins.  
5.2 The parkin and Pink1 proteins act in one pathway 
Although not identical, the flies that have lost Pink1 function share a number of defects 
found in the parkin mutants including shortened lifespan, apoptotic muscle degeneration, 
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male sterility, defects in mitochondrial morphology and disruption of locomotor abilities. 
These mitochondria are lost with age from the dopaminergic neurons of Pink1 mutants. 
While, for the most part, double Pink1-parkin mutants show the same phenotypes as either 
of the single mutants, the overexpression of parkin is able to rescue the mitochondrial defects 
found in Pink1, whereas Pink1 overexpression does not rescue the parkin phenotypes. The 
parkin and Pink1 proteins have been reported to interact physically in at least some contexts 
(Kim et al., 2008; Xiong et al., 2009). This, at least in part, indicates that the Pink1 and parkin 
proteins function in the same pathway with Pink1 functioning upstream of parkin activity. 
This Pink1/parkin pathway is necessary for the integrity of dopaminergic neurons, because 
the loss of neurons due to loss of Pink1 function could be rescued by additional expression 
of parkin (Clark et al., 2006; Park et al., 2006). The contribution of the study of the 
relationship between parkin and Pink1 to our understanding of mitochondrial pathology in 
Parkinson disease highlights the utility of Drosophila to model Parkinson disease. 
Similar to parkin and Pink1, mutations in the Dj-1 gene cause autosomal recessive forms of 
Parkinson disease (Bonifati et al., 2003) and it has been suggested that they will become 
another potential component of this pathway. Drosophila melanogaster has two homologues 
of Dj-1 and is viable when both are deleted or silenced by RNAi transgenes (Menzies et al., 
2005; Meulener et al., 2005; 2006). The loss of Dj-1 activities leads to increased sensitivity to 
oxidative stress when exposed to paraquat or rotenone. However, the overexpression of Dj-
1 does not rescue the Pink1 mutant phenotypes (Yang et al., 2006). The possibility exists that 
Dj-1 may act much further upstream or through a parallel mechanism. However, at this time 
the relationship in unclear and Dj-1 may or may not influence the Pink1/parkin pathway. 
5.3 The parkin and Pink1 proteins co-operate at the mitochondria 
Mitochondria undergo fission and fusion to change shape and share components (Chen & 
Chan, 2009). The fusion of mitochondria requires fusion of both the inner and outer 
mitochondrial membranes.  The control of outer membrane fusion requires the activity of 
the protein mitofusin, and the inner membrane fusion requires the product of the Optic 
atrophy-1 gene. Mitochondrial fission is promoted by the recruitment of dynamin-related 
protein 1 (Drp1) to the mitochondria, and this recruitment requires the activity of Fis1, a 
mitochondrial outer membrane protein. The regulation of this process is essential to the 
maintenance of a healthy cell. 
To focus upon the mitochondria, in the dopaminergic neurons and the adult flight muscles 
of parkin mutants, the mitochondria are swollen with fragmented cristae (Greene et al., 2003; 
Pesah et al., 2004). A similar phenomenon is observed in flies that have lost the function of 
Pink1 (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). During Drosophila 
spermatogenesis, the spermatid’s mitochondria aggregate and fuse to produce the 
nebenkern, a structure composed of two entangled strings of fused mitochondria. During 
subsequent elongation, the nebenkern disentangles to yield two fused structures that are 
maintained throughout the process of spermatogenesis. Whether due to reduced 
mitochondrial fission or excess fusion, in parkin and Pink1 mutants only one mitochondrial 
fusion product has been detected (Deng et al., 2008). These mitochondrial defects, along 
with locomotion defects, flight muscle degeneration, cell death and diminishment of 
dopamine levels in heads, are suppressed both by the directed expression of the pro-fission 
genes drp1 or fis1 and by decreasing levels of the pro-fusion genes mitofusin or opa1 (Deng et 
al., 2008; Park et al., 2009; Poole et al., 2008; Yang et al., 2008). In a Pink1 mutant background, 
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a reduction in the gene copy number of drp1, as seen with mutant heterozygotes, causes 
lethality (Deng et al., 2008; Poole et al., 2008). This clearly suggests that parkin and Pink1 
must act to promote mitochondrial fission. It is extremely important to point out that the 
phenotypes that arise from the loss of parkin or Pink1 are very different from the loss of drp1 
(Deng et al., 2008). This is a strong indication that the Pink1-parkin pathway acts to regulate 
mitochondrial fission machinery.  
5.4 The regulation of Mitophagy by parkin and Pink1 proteins 
The process of mitophagy is a recently described specialized mitochondrial-specific version 
of autophagy (Goldman et al., 2010). In this procedure, the mitochondria undergo 
engulfment by autophagosomes and are degraded. This essential mechanism is absolutely 
dependent upon the dynamics of the continual fission and fusion of the mitochondria that 
alter the size and shape of the organelle and allow the exchange of components. With the 
failure of mitophagy, the quality of cellular respiration is severely diminished as is 
illustrated through the accumulation of oxidized proteins. Through the regulation of the 
fission/fusion dynamics of the cellular mitochondria, the Pink1 and parkin collaborate to 
contribute to this process. 
First of all, although the parkin E3 ubiquitin ligase can target toxic proteins for proteasomal 
degradation, as the loss of parkin results in the accumulation of toxic proteins and 
overexpression can suppress toxicity of potential targets, other cellular processes can be 
regulated by ubiquitination by parkin (Geisler et al., 2009). With this in mind, a mechanism 
has been proposed that outlines the potential roles of the parkin and Pink1 proteins in the 
regulation of mitochondrial dynamics, changes in which can lead to alterations in the 
process of mitophagy (Geisler et al., 2009; Narendra et al., 2009; Vives-Bauza et al., 2010; 
Ziviani et al., 2010). The recruitment of parkin from the cytoplasm to the mitochondria 
depends on the activity of the Pink1 kinase. Pink1 is localized to the outer mitochondrial 
membrane through a well-conserved mitochondrial targeting signal peptide located near 
the amino-terminus of the protein (Zhou et al., 2008).  This arrangement leaves the carboxy-
terminal kinase-containing remainder of the protein exposed to the cytoplasm. It is 
proposed that under normal conditions, the tethered Pink1 protein is cleaved in a 
constitutive way to release the portion of Pink1 that contains the kinase activity into the 
cytoplasm (Narendra et al., 2009; Vives-Bauza et al., 2010; Ziviani et al., 2010). As a result, 
under standard conditions, Pink1 activity at the mitochondrial membrane is maintained at a 
steady but low level.  
However, when stressed mitochondria undergo a critical amount of damage, the routine 
degradation of the Pink1 kinase is discontinued (Narendra et al., 2009; Vives-Bauza et al., 
2010; Ziviani et al., 2010). This leaves intact and active versions of Pink1 to accumulate at the 
mitochondrial membrane in response to the termination of Pink1 inactivation. The initiation 
and maintenance of the accumulation of Pink1 may depend upon a signal generated when 
the mitochondria are not able to maintain membrane potential. Although the Rhomboid-7 
protease is a candidate enzyme that can cleave Pink1 (Whitworth et al., 2008), this protease 
may not be the one responsible for this activity in response to mitochondria signalling for 
destruction. In the first major step of this process, the result is the differential identification 
of damaged mitochondria through the build up of active Pink1 activity bound and secured 
to the outer mitochondrial membrane. According to this mechanism, the next step in the 
regulation of mitophagy depends upon the recruitment of the parkin E3 ubiquitin ligase 
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though Pink1 activity to the outer mitochondrial membrane (Narendra et al., 2009; Vives-
Bauza et al., 2010; Ziviani et al., 2010). Recruitment of parkin to the mitochondrial 
membrane depends upon the localization of the Pink1 kinase to the mitochondria. An 
alternative method of mitochondrial targeting of Pink1 also recruits parkin (Narendra et al., 
2009). Finally, the presence of the parkin ligase at the mitochondria results in the 
ubiquitination and subsequent degradation of the fusion-promoting outer mitochondrial 
membrane protein mitofusin (Ziviani et al., 2010). The mitofusin protein has been shown to 
accumulate with the loss of Pink1 and parkin gene functions. If this proposal holds true, the 
initiation of mitophagy may very well depend upon signaling through the ubiquitination of 
mitofusin. In turn, whether mitofusin is targeted for degradation or modified to a form that 
no longer contributes to the process, this situation leads to the prevention of the fusion of 
the outer mitochondrial membrane. Although there is no evidence that fission is directly 
influenced, the subsequent failure of damaged mitochondria to be isolated would likely 
result from their loss of the ability to undergo proper segregation.  
In summary, when mitochondria accumulate sufficient damage, the Pink1 protein becomes 
stabilized at the mitochondria. This acts to recruit parkin to the damaged mitochondria that 
in turn causes degradation or modification of mitofusin to promote mitochondrial fission 
and mitophagy to remove these damaged mitochondria. In Pink1/parkin mediated 
Parkinson disease, the damaged mitochondria are not cleared as efficiently to result in 
cellular damage.  
6. The future of drosophila models of Parkinson disease 
Drosophila is proving to have great advantages in the genetic and cell biological study of 
Parkinson disease. As more genes are found to be associated with Parkinson disease, further 
applications of reverse genetics should lead to greater understanding of the disease. The 
Drosophila phenotypes offer many diverse clues that may benefit from greater scrutiny. As 
well as future screens that modify the more obvious phenotypes such as male sterility, 
muscle degeneration, abnormal wing positioning, locomotion defects as well as 
mitochondrial defects in multiple tissues in young adults, these can be examined/scored for 
suppression or enhancement without having to carry out aging studies that can span 
months. Studies of candidate genes that may modify the activities of genes that mediate 
familial Parkinson disease are rigorous, but allow for rapid and straightforward means to 
deduce mechanisms. Given that mitochondria defects accumulate during normal aging, 
identification of multiple means to activate mitophagy may have applications to many 
aspects of aging. Drosophila provides an indispensable and unique opportunity to 
contribute to the Parkinson disease field. 
7. Conclusion 
To summarize, the recent expansion of research interest in the well understood laboratory 
organism Drosophila melanogaster to provide highly informative models of Parkinson disease 
demonstrates some of the great advantages that this system has to offer. The first model of 
Parkinson disease, one based on the toxic expression of the human alpha-synuclein gene, has 
allowed a great deal of investigation into various biological factors, such as protein folding, 
oxidative stress and protein detoxification, that may contribute to the disease. Studies of 
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Lrrk/LRRK2 have revealed roles for the management of dopamine handling, the control of 
protein synthesis and the initiation of programmed cell death in models of Parkinson 
disease. Further modelling of Parkinson disease through careful evaluation of parkin and 
Pink1 loss-of–function in Drosophila has revealed that these two genes contribute to a 
pathway where the parkin E3 ubiquitin ligase is under the regulatory control of the Pink1 
protein kinase. In flies, the relationship between parkin and Pink1 has been extended from 
the neurons to other tissues including the mitochondrial-rich flight muscle and the male 
gametes. This has led to investigation of the products of these highly conserved genes in the 
processes that promote mitochondrial survival. The routine participation of parkin and Pink1 
in mitochondrial activities reveals that the loss of the fusion/fission dynamic can result in 
the failure of the cells to adequately deal with mitochondria that present a burden to the 
health of the cell. Future study of Parkinson disease in Drosophila models will continue to 
reveal much about the basis of this disease. As the past century has made clear, over and 
over again, investigations that apply our collective knowledge of the genetics and biology of 
Drosophila melanogaster to explore the fundamentals of disease, such as Parkinson disease, 
are very difficult to ignore. 
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